Friday, July 10, 2026

pharma · Steroid refractory Acute Graft versus host Disease · moderate to severe atopic dermatitis

Medac Gesellschaft fuer

Medac Gesellschaft fuer clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

EU HQ
EMA registrant Type
Company details
Status
Public
HQ
EU
Programs
3
Drugs
14
Patents
0
Intelligence · Clinical Programs

Medac Gesellschaft fuer projects

3 ClinicalTrials.gov programs sponsored by Medac Gesellschaft fuer.

Medac Gesellschaft fuer has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. MC-MSC.1/aGvHD

    Medac Gesellschaft fuer klinische Spezialpraeparate mbH

    Steroid refractory Acute Graft versus host Disease

    phase 3 small molecule active

    1 trial
  2. MC-MTX.18/AD

    Medac Gesellschaft fuer klinische Spezialpraeparate mbH

    moderate to severe atopic dermatitis

    phase 3 small molecule active

    1 trial
  3. MC-FludT.18/QT

    Medac Gesellschaft fuer klinische Spezialpraeparate mbH

    Subjects with AML ( Acute myeloid leukaemia) or MDS (Myelodysplastic syndrome) undergoing allogeneic hematopoietic stem cell transplantation

    phase 1 other active

    1 trial

Frequently asked questions

How many clinical projects does Medac Gesellschaft fuer have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.